FRI0549 Sleqol is responsive to changes in health-related quality of life due to treatment in systemic lupus erythematosus
Identifieur interne : 002D68 ( Main/Exploration ); précédent : 002D67; suivant : 002D69FRI0549 Sleqol is responsive to changes in health-related quality of life due to treatment in systemic lupus erythematosus
Auteurs : K. P. Leong [Singapour] ; J. C.-W. Tan [Singapour] ; B. Y. H. Thong [Singapour] ; T. Y. Lian [Singapour] ; E. T. Koh [Singapour] ; K. O. Kong [Singapour] ; W. G. Law [Singapour] ; H. H. Chng [Singapour] ; G. Y. L. Chan [Singapour] ; F. L.-A. Chia [Singapour] ; J. W. L. Tan [Singapour] ; H. S. Howe [Singapour]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-06.
English descriptors
- Teeft :
- Abatacept, Abbvie, Bdmard, Cyclophosphamide, Days supply, Dohme, Gout patients, Last claim, Lupus, Medicare, Medicare population, Mycophenolate, Oral cyclophosphamide, Pfizer, Roche, Sharp dohme, Sleqol, Squibb, States background, Subsequent switch rates, Switch cohort, Systemic lupus erythematosus, Third bdmard.
Abstract
Background Various generic quality-of-life QoL (QoL) scales such as MOS 36-Item Short-Form Health Survey (SF-36) and disease-specific ones such as systemic lupus erythematosus QoL (SLEQOL) have been used to study the QoL of lupus patients. Most of the studies are cross-sectional and, consequently, information about the responsiveness of such instruments is scant. Objectives We studied the responsiveness of SLEQOL and SF-36 in lupus patient as they receive new drug treatment. Methods We selected patients from our prospective SLE registry who were prescribed new medications. We studied the differences in the QoL at study visits just before and just after the introduction of azathioprine, oral cyclophosphamide, intravenous cyclophosphamide, danazol, cyclosporine A, mycophenolate or hydroxychloroquine in an intention-to-treat manner. We collected clinical data and scores from SF-36, SLEQOL, Rheumatology Attitudes Index (RAI), SLE Disease Activity Index (SLEDAI) and revised Systemic Lupus Activity Measure (SLAM-R). Results There were 216 SLE patients (with 194 females) with 303 new drug initiations. The mean age was 36.23 ± 11.78 years. The mean age of diagnosis was 27.65 ± 10.34 years. Using SLEQOL, we found that the use of IV cyclophosphamide, mycophenolate and azathioprine is associated with significant improvements in QoL, in contrast to oral cyclophosphamide, cyclosporin A, danazol and hydroxychloroquine. IV cyclophosphamide is associated with improvement in the physical functioning, activities and self-image domains of SLEQOL, mycophenolate in the treatment and self-image domains and azathioprine in the activities and mood domains. SF-36 reflected QoL change with the use of IV cyclophosphamide (general health domain) and mycophenolate (physical functioning and role physical). Conclusions SLEQOL is responsive to the changes in QoL of SLE patients as they receive new medications. It distinguishes the differential effects on QoL of the various drugs. Different domains of the SLEQOL and SF-36 improved with the various medications. SLEQOL may be useful as an outcome measure in SLE clinical trials. Disclosure of Interest None Declared
Url:
DOI: 10.1136/annrheumdis-2013-eular.1676
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B75
- to stream Istex, to step Curation: 000B75
- to stream Istex, to step Checkpoint: 000859
- to stream Main, to step Merge: 002D82
- to stream Main, to step Curation: 002D68
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">FRI0549 Sleqol is responsive to changes in health-related quality of life due to treatment in systemic lupus erythematosus</title><author><name sortKey="Leong, K P" sort="Leong, K P" uniqKey="Leong K" first="K. P." last="Leong">K. P. Leong</name></author><author><name sortKey="Tan, J C W" sort="Tan, J C W" uniqKey="Tan J" first="J. C.-W." last="Tan">J. C.-W. Tan</name></author><author><name sortKey="Thong, B Y H" sort="Thong, B Y H" uniqKey="Thong B" first="B. Y. H." last="Thong">B. Y. H. Thong</name></author><author><name sortKey="Lian, T Y" sort="Lian, T Y" uniqKey="Lian T" first="T. Y." last="Lian">T. Y. Lian</name></author><author><name sortKey="Koh, E T" sort="Koh, E T" uniqKey="Koh E" first="E. T." last="Koh">E. T. Koh</name></author><author><name sortKey="Kong, K O" sort="Kong, K O" uniqKey="Kong K" first="K. O." last="Kong">K. O. Kong</name></author><author><name sortKey="Law, W G" sort="Law, W G" uniqKey="Law W" first="W. G." last="Law">W. G. Law</name></author><author><name sortKey="Chng, H H" sort="Chng, H H" uniqKey="Chng H" first="H. H." last="Chng">H. H. Chng</name></author><author><name sortKey="Chan, G Y L" sort="Chan, G Y L" uniqKey="Chan G" first="G. Y. L." last="Chan">G. Y. L. Chan</name></author><author><name sortKey="Chia, F L A" sort="Chia, F L A" uniqKey="Chia F" first="F. L.-A." last="Chia">F. L.-A. Chia</name></author><author><name sortKey="Tan, J W L" sort="Tan, J W L" uniqKey="Tan J" first="J. W. L." last="Tan">J. W. L. Tan</name></author><author><name sortKey="Howe, H S" sort="Howe, H S" uniqKey="Howe H" first="H. S." last="Howe">H. S. Howe</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DB5B03CE9C264D45B955C7BE924971D83E41376C</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1136/annrheumdis-2013-eular.1676</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-CJF16TVZ-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000B75</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B75</idno><idno type="wicri:Area/Istex/Curation">000B75</idno><idno type="wicri:Area/Istex/Checkpoint">000859</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000859</idno><idno type="wicri:doubleKey">0003-4967:2013:Leong K:fri:sleqol:is</idno><idno type="wicri:Area/Main/Merge">002D82</idno><idno type="wicri:Area/Main/Curation">002D68</idno><idno type="wicri:Area/Main/Exploration">002D68</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">FRI0549 Sleqol is responsive to changes in health-related quality of life due to treatment in systemic lupus erythematosus</title><author><name sortKey="Leong, K P" sort="Leong, K P" uniqKey="Leong K" first="K. P." last="Leong">K. P. Leong</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Rheumatology, Allergy and Immunology, TAN TOCK SENG HOSPITAL, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Tan, J C W" sort="Tan, J C W" uniqKey="Tan J" first="J. C.-W." last="Tan">J. C.-W. Tan</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Rheumatology, Allergy and Immunology, TAN TOCK SENG HOSPITAL, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Thong, B Y H" sort="Thong, B Y H" uniqKey="Thong B" first="B. Y. H." last="Thong">B. Y. H. Thong</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Rheumatology, Allergy and Immunology, TAN TOCK SENG HOSPITAL, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Lian, T Y" sort="Lian, T Y" uniqKey="Lian T" first="T. Y." last="Lian">T. Y. Lian</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Rheumatology, Allergy and Immunology, TAN TOCK SENG HOSPITAL, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Koh, E T" sort="Koh, E T" uniqKey="Koh E" first="E. T." last="Koh">E. T. Koh</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Rheumatology, Allergy and Immunology, TAN TOCK SENG HOSPITAL, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Kong, K O" sort="Kong, K O" uniqKey="Kong K" first="K. O." last="Kong">K. O. Kong</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Rheumatology, Allergy and Immunology, TAN TOCK SENG HOSPITAL, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Law, W G" sort="Law, W G" uniqKey="Law W" first="W. G." last="Law">W. G. Law</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Rheumatology, Allergy and Immunology, TAN TOCK SENG HOSPITAL, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Chng, H H" sort="Chng, H H" uniqKey="Chng H" first="H. H." last="Chng">H. H. Chng</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Rheumatology, Allergy and Immunology, TAN TOCK SENG HOSPITAL, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Chan, G Y L" sort="Chan, G Y L" uniqKey="Chan G" first="G. Y. L." last="Chan">G. Y. L. Chan</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Rheumatology, Allergy and Immunology, TAN TOCK SENG HOSPITAL, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Chia, F L A" sort="Chia, F L A" uniqKey="Chia F" first="F. L.-A." last="Chia">F. L.-A. Chia</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Rheumatology, Allergy and Immunology, TAN TOCK SENG HOSPITAL, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Tan, J W L" sort="Tan, J W L" uniqKey="Tan J" first="J. W. L." last="Tan">J. W. L. Tan</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Rheumatology, Allergy and Immunology, TAN TOCK SENG HOSPITAL, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Howe, H S" sort="Howe, H S" uniqKey="Howe H" first="H. S." last="Howe">H. S. Howe</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Rheumatology, Allergy and Immunology, TAN TOCK SENG HOSPITAL, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2013-06">2013-06</date><biblScope unit="volume">72</biblScope><biblScope unit="issue">Suppl 3</biblScope><biblScope unit="page" from="A561">A561</biblScope></imprint><idno type="ISSN">0003-4967</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abatacept</term><term>Abbvie</term><term>Bdmard</term><term>Cyclophosphamide</term><term>Days supply</term><term>Dohme</term><term>Gout patients</term><term>Last claim</term><term>Lupus</term><term>Medicare</term><term>Medicare population</term><term>Mycophenolate</term><term>Oral cyclophosphamide</term><term>Pfizer</term><term>Roche</term><term>Sharp dohme</term><term>Sleqol</term><term>Squibb</term><term>States background</term><term>Subsequent switch rates</term><term>Switch cohort</term><term>Systemic lupus erythematosus</term><term>Third bdmard</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Background Various generic quality-of-life QoL (QoL) scales such as MOS 36-Item Short-Form Health Survey (SF-36) and disease-specific ones such as systemic lupus erythematosus QoL (SLEQOL) have been used to study the QoL of lupus patients. Most of the studies are cross-sectional and, consequently, information about the responsiveness of such instruments is scant. Objectives We studied the responsiveness of SLEQOL and SF-36 in lupus patient as they receive new drug treatment. Methods We selected patients from our prospective SLE registry who were prescribed new medications. We studied the differences in the QoL at study visits just before and just after the introduction of azathioprine, oral cyclophosphamide, intravenous cyclophosphamide, danazol, cyclosporine A, mycophenolate or hydroxychloroquine in an intention-to-treat manner. We collected clinical data and scores from SF-36, SLEQOL, Rheumatology Attitudes Index (RAI), SLE Disease Activity Index (SLEDAI) and revised Systemic Lupus Activity Measure (SLAM-R). Results There were 216 SLE patients (with 194 females) with 303 new drug initiations. The mean age was 36.23 ± 11.78 years. The mean age of diagnosis was 27.65 ± 10.34 years. Using SLEQOL, we found that the use of IV cyclophosphamide, mycophenolate and azathioprine is associated with significant improvements in QoL, in contrast to oral cyclophosphamide, cyclosporin A, danazol and hydroxychloroquine. IV cyclophosphamide is associated with improvement in the physical functioning, activities and self-image domains of SLEQOL, mycophenolate in the treatment and self-image domains and azathioprine in the activities and mood domains. SF-36 reflected QoL change with the use of IV cyclophosphamide (general health domain) and mycophenolate (physical functioning and role physical). Conclusions SLEQOL is responsive to the changes in QoL of SLE patients as they receive new medications. It distinguishes the differential effects on QoL of the various drugs. Different domains of the SLEQOL and SF-36 improved with the various medications. SLEQOL may be useful as an outcome measure in SLE clinical trials. Disclosure of Interest None Declared</div></front></TEI><affiliations><list><country><li>Singapour</li></country></list><tree><country name="Singapour"><noRegion><name sortKey="Leong, K P" sort="Leong, K P" uniqKey="Leong K" first="K. P." last="Leong">K. P. Leong</name></noRegion><name sortKey="Chan, G Y L" sort="Chan, G Y L" uniqKey="Chan G" first="G. Y. L." last="Chan">G. Y. L. Chan</name><name sortKey="Chia, F L A" sort="Chia, F L A" uniqKey="Chia F" first="F. L.-A." last="Chia">F. L.-A. Chia</name><name sortKey="Chng, H H" sort="Chng, H H" uniqKey="Chng H" first="H. H." last="Chng">H. H. Chng</name><name sortKey="Howe, H S" sort="Howe, H S" uniqKey="Howe H" first="H. S." last="Howe">H. S. Howe</name><name sortKey="Koh, E T" sort="Koh, E T" uniqKey="Koh E" first="E. T." last="Koh">E. T. Koh</name><name sortKey="Kong, K O" sort="Kong, K O" uniqKey="Kong K" first="K. O." last="Kong">K. O. Kong</name><name sortKey="Law, W G" sort="Law, W G" uniqKey="Law W" first="W. G." last="Law">W. G. Law</name><name sortKey="Lian, T Y" sort="Lian, T Y" uniqKey="Lian T" first="T. Y." last="Lian">T. Y. Lian</name><name sortKey="Tan, J C W" sort="Tan, J C W" uniqKey="Tan J" first="J. C.-W." last="Tan">J. C.-W. Tan</name><name sortKey="Tan, J W L" sort="Tan, J W L" uniqKey="Tan J" first="J. W. L." last="Tan">J. W. L. Tan</name><name sortKey="Thong, B Y H" sort="Thong, B Y H" uniqKey="Thong B" first="B. Y. H." last="Thong">B. Y. H. Thong</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DB5B03CE9C264D45B955C7BE924971D83E41376C
|texte= FRI0549 Sleqol is responsive to changes in health-related quality of life due to treatment in systemic lupus erythematosus
}}
| This area was generated with Dilib version V0.6.34. |  |